Astellas, MD Anderson ally in AML
Astellas Pharma Inc. and the University of Texas’ MD Anderson Cancer Center are teaming up to research and develop a treatment for acute myeloid leukemia (AML). (Apr.)
Tech Transfer Deals, May 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2015.
More from Deals
More from Business
• By
In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.
• By
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
• By
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.